TrialJournal of hematology & oncology2021

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.

Michael Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.